breakthrough infections – Page 11 – Communicable Diseases Research

Adaptive Immune Responses and Immunity to SARS-CoV-2

SARS-CoV-2에 대한 적응 면역 반응 및 면역

Review

Published on 2022-05-042022-09-11
Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 변종,

Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2

SARS-CoV-2에 대한 교차 반응성 점막 및 전신 항체 반응을 위한 열안정성 소단위 백신의 비강내 전달

Article

Published on 2022-05-032022-09-11
Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단,

[키워드] ACE2 addition Against Alpha angiotensin angiotensin converting enzyme angiotensin converting enzyme 2 anti-RBD Anti-RBD antibody antibody Antibody Response Antibody responses Antibody titer Antibody titers approved Beta binding binding domain Breakthrough infection breakthrough infections chitosan circulation COVID-19 COVID-19 vaccines CpG cross-reactive delivery Delta variants domain Efficacy effort enzyme exclusion FIVE genetic material help Hesitancy IgA antibodies IgG1 IgG2a IL-12 Immunity immunization IMPROVE induce inhibited interleukin interleukin-12 intranasal intranasal vaccination intranasally isotype Laboratory mice mucosal mucosal immunity mutant oligonucleotide polypeptide Prevent PROTECT RBD RBD-specific antibodies RBD-specific antibody receptor Receptor binding domain receptor binding domain (RBD) reduce respiratory respiratory viruses response responses room temperature SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants specific antibodies stability subcutaneous vaccination subunit Subunit vaccine systemic temperature the vaccine thermostable upper respiratory tract vaccination Vaccine Vaccine development Vaccine hesitancy vaccine platform variants virus
[DOI] 10.3389/fimmu.2022.858904 PMC 바로가기 [Article Type] Article

Transmission and Infectious SARS-CoV-2 Shedding Kinetics in Vaccinated and Unvaccinated Individuals

예방 접종 및 예방 접종을 받지 않은 개인의 전염 및 전염성 SARS-CoV-2 배출 역학

Article

Published on 2022-05-022022-09-11
Journal: JAMA Network Open [Category] COVID19(2023년), SARS, 변종, 치료기술,

[키워드] age attack rate Breakthrough infection breakthrough infections Care Caregivers Cell culture Chain Reaction cohort study Community comparable contribute COVID-19 COVID-19 infection COVID-19 vaccination COVID-19 vaccinations Culture delta variant diagnosed with COVID-19 evaluate Evidence female genomic genomic RNA groups Health care health care workers hospital Hospitalization individual individuals Infection initial Inpatients Kinetics less median median age Mild outcome Patient performed polymerase chain polymerase chain reaction residence Saliva saliva samples SARS-CoV-2 secondary secondary attack rate secondary transmission shedding significantly South Korea Spread symptom onset Transmission vaccinated individual Vaccination Status Viral load viral shedding virus virus culture was measured with COVID-19
[DOI] 10.1001/jamanetworkopen.2022.13606 PMC 바로가기 [Article Type] Article

Risk and Outcome of Breakthrough COVID-19 Infections in Vaccinated Patients With Cancer: Real-World Evidence From the National COVID Cohort Collaborative

백신 접종을 받은 암 환자의 획기적인 COVID-19 감염의 위험과 결과: 국가 COVID 코호트 협력의 실제 증거

Article

Published on 2022-05-012022-09-11
Journal: Journal of clinical oncology : official journal of [Category] COVID19(2023년), SARS, 변종,

[키워드] 95% CI adjusted age analyzed BNT162b2 BNT162b2 vaccine Bone marrow Bone marrow transplantation booster Breakthrough infection breakthrough infections Cancer cancers Cohort controls COVID COVID-19 COVID-19 case COVID-19 cases COVID-19 infection COVID-19 infections Evidence hematologic Hematologic malignancy higher risk identify immunosuppressive effect increased risk leukemia Logistic regression lymphoid lymphoma malignancies medications Moderna mRNA COVID-19 vaccine mRNA COVID-19 vaccines mRNA-1273 Multiple myeloma Myeloma National new SARS-CoV-2 Odds ratios outcome outcomes Patient patients Patients with cancer Pfizer ranged risk SARS-COV-2 infection SARS-CoV-2 variants Sex significantly higher smoking smoking status Solid solid tumors Tumor tumors vaccination Vaccine vaccine dose variants was reduced
[DOI] 10.1200/JCO.21.02419 PMC 바로가기 [Article Type] Article

Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects

의료 종사자 및 노인 대상에서 세 번째 mRNA 백신 접종 후 SARS-CoV-2 Omicron 변이체에 대한 중화 항체

Article

Published on 2022-05-012022-09-11
Journal: European Journal of Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술,

[키워드] administration age antibody Antibody responses B.1.1.529 Beta booster booster vaccination Breakthrough infection breakthrough infections collected Concentration Coronavirus disease 2019 COVID-19 cross-protective cross-reactive Delta detectable dose expected HCW HCWs Health care Health care worker health care workers IgG IgG antibody mRNA vaccination mRNA vaccine Mutation NAb NAb titer NAb titers NAbs neutralization Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody nursing home omicron Postinfection raised reduced remained SARS-CoV-2 severe COVID-19 significantly Spike protein subject subjects subsequent the antibody response the spike protein vaccination vaccine dose variant variants variants of concern WT virus
[DOI] 10.1002/eji.202149785 PMC 바로가기 [Article Type] Article

The effect of a third BNT162b2 vaccine on breakthrough infections in health care workers: a cohort analysis

의료 종사자의 돌발성 감염에 대한 세 번째 BNT162b2 백신의 효과: 코호트 분석

Article

Published on 2022-05-012022-09-11
Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 변종,

[키워드] 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 all age groups BNT162b2 BNT162b2 mRNA vaccine BNT162b2 vaccine booster booster dose Breakthrough infection breakthrough infections Care Cohort cohort analysis coronavirus coronavirus disease Coronavirus disease 2019 defined delta variant dose follow-up period HCW HCWs Health Health care Health care worker health care workers indicate infection rate infection rates infections initiated Jerusalem mass vaccination Ministry of Health protective effect Relative risk risk SARS-CoV-2 severe acute respiratory syndrome Coronavirus significantly lower third dose two-dose regimen vaccination Vaccine vaccine dose variant
[DOI] 10.1016/j.cmi.2022.01.019 PMC 바로가기 [Article Type] Article

Genomic, immunological, and clinical analysis of COVID-19 vaccine breakthrough infections in Beijing, China

중국 베이징에서 코로나19 백신 돌발 감염의 게놈, 면역학 및 임상 분석

Article

Published on 2022-05-012022-09-11
Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Analysis Asymptomatic asymptomatic and mild cases Beijing both groups Breakthrough infection breakthrough infections CD4 Chain Reaction Characteristics China circulating clinical analysis Clinical outcome coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 cases COVID-19 vaccine COVID-19 vaccines database Delta delta variant Delta variants Efficacy elevated evaluate genomic IgG titer IgG titers immunological immunological characterization in both groups Infection lymphocyte median time Mild mild case mild cases no significant difference pandemic Patient patients polymerase chain polymerase chain reaction Quantitative SARS-CoV-2 sequenced severe acute respiratory syndrome Coronavirus severe disease significantly significantly increased significantly lower T lymphocyte two groups two patients Vaccine vaccine breakthrough infections variant variants viral shedding whole genome whole-genomic analysis.
[DOI] 10.1002/jmv.27636 PMC 바로가기 [Article Type] Article

Hospitalised patients with breakthrough COVID-19 following vaccination during two distinct waves in Israel, January to August 2021: a multicentre comparative cohort study

2021년 1월부터 8월까지 이스라엘에서 두 차례에 걸쳐 백신 접종 후 획기적인 COVID-19로 입원한 환자: 다기관 비교 코호트 연구

Multicenter Study

Published on 2022-05-012022-09-11
Journal: Eurosurveillance [Category] COVID19(2023년), SARS, 변종,

SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022

SARS-CoV-2 Omicron 변이체 BA.2 중화, Comirnaty 또는 CoronaVac 백신 접종, 감염 또는 돌발성 감염, 홍콩, 2020년에서 2022년까지

Article

Published on 2022-05-012022-09-11
Journal: Eurosurveillance [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술,

[키워드] affecting antibody Beta BNT162b2 Breakthrough infection breakthrough infections circulation comparable CoronaVac Delta detectable dose elicited evaluated followed by help Hong Kong hybrid-immunity individual individuals Infection neutralisation neutralisation test neutralisation tests Neutralising Antibodies neutralising antibody neutralising antibody response neutralising antibody titre neutralising antibody titres neutralization omicron other variant other variants PRNT reduction response SARS-CoV-2 SARS-COV-2 infection sera significantly single vaccine subvariant BA.1 subvariant BA.2 symptomatic infection titre titres uninfected vaccination Vaccine vaccinee vaccinees variant viruses wild type
[DOI] 10.2807/1560-7917.ES.2022.27.18.2200178 PMC 바로가기 [Article Type] Article

Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection

전신 및 점막 IgA 반응은 SARS-CoV-2 mRNA 백신 접종에 대한 반응으로 다양하게 유도되며 후속 감염에 대한 보호와 관련이 있습니다.

Article

Published on 2022-05-012022-09-11
Journal: Mucosal Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, 진단, 치료기술,

[키워드] anti-SARS-CoV-2 Anti-spike booster Breakthrough infection breakthrough infections collected comparable COVID-19 COVID-19 mRNA Vaccination COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines dose elicit Examining exhibited groups IgA IgA response IgG IgG level IgG levels in some infect infected with SARS-CoV-2 Infection Kinetics kinetics of antibody Local mRNA mRNA COVID-19 vaccine mRNA COVID-19 vaccines mRNA vaccination mucosal IgA response oral cavity participant Participants persist positive preventing infection prospective cohort provoke RBD RBD IgA receiving reduce respiratory Saliva SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants second dose serum subsequent systemic These data Transmission upper respiratory tract utility
[DOI] 10.1038/s41385-022-00511-0 PMC 바로가기 [Article Type] Article